Law & Medicine

Oral contraception and medical liability


 

References

The prime reason for disallowing a wrongful life action is that life, even if imperfect, is always preferable to non-life. Besides, it will be impossible to assess the quantum of damages, because this necessarily requires placing a monetary worth on human existence.

The seminal case is the 1967 New Jersey decision of Gleitman v. Cosgrove (227 A.2d 689 [N.J. 1967]), but the state’s position has since changed. In Berman v. Allan (404 A.2d 8 [N.J. 1979]), the court allowed damages for maternal emotional distress, though not for medical and other expenses of raising the child.

Overall, the law of wrongful life appears to be increasingly willing to award damages to the mother for the physical, emotional, and financial costs of pregnancy and delivery, but not the cost associated with the normal rearing of a healthy child.

The legal situation is quite different for a lawsuit filed by the child, who in essence is arguing that he/she should not have been born at all. Courts continue to refuse a claim brought by a healthy infant for wrongful life, adopting the reasoning in Berman that the infant has not suffered any damage cognizable at law by being brought into existence. Even an infant with birth disabilities will not prevail in the majority of jurisdictions, with California being a notable exception.

Dr. Tan is emeritus professor of medicine and former adjunct professor of law at the University of Hawaii, and currently directs the St. Francis International Center for Healthcare Ethics in Honolulu. This article is meant to be educational and does not constitute medical, ethical, or legal advice. Some of the articles in this series are adapted from the author’s 2006 book, “Medical Malpractice: Understanding the Law, Managing the Risk,” and his 2012 Halsbury treatise, “Medical Negligence and Professional Misconduct.” For additional information, readers may contact the author at siang@hawaii.edu.

Pages

Recommended Reading

Q&A with the FDA: Implementing the Pregnancy and Lactation Labeling Rule
MDedge Neurology
FDA advisors urge physician certification for flibanserin
MDedge Neurology
Delivery mortality and complications higher in epileptic women
MDedge Neurology
Estrogen therapy linked to brain atrophy in women with diabetes
MDedge Neurology
Pregnancy registries add to the clinical picture
MDedge Neurology
Unvetted drug indications mean safety uncertainties
MDedge Neurology
Breastfeeding protects against postpartum MS relapse
MDedge Neurology
Recall issued on U.S. Compounding sterile products
MDedge Neurology
Raloxifene ineffective for treating AD patients
MDedge Neurology
AES: Hormonal contraceptives can boost seizures in epileptics
MDedge Neurology